Botulinum toxin in movement disorders

Spiridon Papapetropoulos, Carlos Singer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Botulinum toxin inhibits the vesicular release of acetylcholine in the neuromuscular junction, resulting in a transient, localized paralysis when small doses are injected. The successful use of serotypes A and B in conditions with muscle overactivity such as dystonia and spasticity has been well established. Apart from approved indications, treatment with botulinum toxin injections is attempted in a variety of new areas of neurology, including tremor, tics, and myoclonus. This article provides an update on the uses of botulinum toxin in the field of movement disorders and draws special attention to theoretical and practical treatment issues of primary and secondary dystonic disorders. Long-term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for the increasing number of off-label indications. However, controlled studies for many conditions are lacking, and more clinical trials in many different areas are warranted.

Original languageEnglish
Pages (from-to)183-194
Number of pages12
JournalSeminars in Neurology
Volume27
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

Botulinum Toxins
Movement Disorders
Dystonic Disorders
Tics
Myoclonus
Dystonia
Neuromuscular Junction
Tremor
Neurology
Paralysis
Acetylcholine
Therapeutics
Clinical Trials
Muscles
Injections

Keywords

  • Botulinum toxin
  • Dystonia
  • Movement disorders

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Botulinum toxin in movement disorders. / Papapetropoulos, Spiridon; Singer, Carlos.

In: Seminars in Neurology, Vol. 27, No. 2, 01.04.2007, p. 183-194.

Research output: Contribution to journalArticle

Papapetropoulos, Spiridon ; Singer, Carlos. / Botulinum toxin in movement disorders. In: Seminars in Neurology. 2007 ; Vol. 27, No. 2. pp. 183-194.
@article{db45b6e65487466c95eaa0df7e5a9b66,
title = "Botulinum toxin in movement disorders",
abstract = "Botulinum toxin inhibits the vesicular release of acetylcholine in the neuromuscular junction, resulting in a transient, localized paralysis when small doses are injected. The successful use of serotypes A and B in conditions with muscle overactivity such as dystonia and spasticity has been well established. Apart from approved indications, treatment with botulinum toxin injections is attempted in a variety of new areas of neurology, including tremor, tics, and myoclonus. This article provides an update on the uses of botulinum toxin in the field of movement disorders and draws special attention to theoretical and practical treatment issues of primary and secondary dystonic disorders. Long-term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for the increasing number of off-label indications. However, controlled studies for many conditions are lacking, and more clinical trials in many different areas are warranted.",
keywords = "Botulinum toxin, Dystonia, Movement disorders",
author = "Spiridon Papapetropoulos and Carlos Singer",
year = "2007",
month = "4",
day = "1",
doi = "10.1055/s-2007-971171",
language = "English",
volume = "27",
pages = "183--194",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Botulinum toxin in movement disorders

AU - Papapetropoulos, Spiridon

AU - Singer, Carlos

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Botulinum toxin inhibits the vesicular release of acetylcholine in the neuromuscular junction, resulting in a transient, localized paralysis when small doses are injected. The successful use of serotypes A and B in conditions with muscle overactivity such as dystonia and spasticity has been well established. Apart from approved indications, treatment with botulinum toxin injections is attempted in a variety of new areas of neurology, including tremor, tics, and myoclonus. This article provides an update on the uses of botulinum toxin in the field of movement disorders and draws special attention to theoretical and practical treatment issues of primary and secondary dystonic disorders. Long-term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for the increasing number of off-label indications. However, controlled studies for many conditions are lacking, and more clinical trials in many different areas are warranted.

AB - Botulinum toxin inhibits the vesicular release of acetylcholine in the neuromuscular junction, resulting in a transient, localized paralysis when small doses are injected. The successful use of serotypes A and B in conditions with muscle overactivity such as dystonia and spasticity has been well established. Apart from approved indications, treatment with botulinum toxin injections is attempted in a variety of new areas of neurology, including tremor, tics, and myoclonus. This article provides an update on the uses of botulinum toxin in the field of movement disorders and draws special attention to theoretical and practical treatment issues of primary and secondary dystonic disorders. Long-term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for the increasing number of off-label indications. However, controlled studies for many conditions are lacking, and more clinical trials in many different areas are warranted.

KW - Botulinum toxin

KW - Dystonia

KW - Movement disorders

UR - http://www.scopus.com/inward/record.url?scp=34147187742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147187742&partnerID=8YFLogxK

U2 - 10.1055/s-2007-971171

DO - 10.1055/s-2007-971171

M3 - Article

C2 - 17390263

AN - SCOPUS:34147187742

VL - 27

SP - 183

EP - 194

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 2

ER -